GHRP-2

Vialdyne buyer fit

Overview

GHRP-2, also catalogued as Pralmorelin, is a synthetic hexapeptide secretagogue acting at the ghrelin / growth-hormone secretagogue receptor (GHSR) within the broader GHRP family. The peptide sequence is sometimes reported with minor variants across the literature; the standard form supplied here is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Pharmacology produces robust GH release, which is what underwrote the historical Japanese approval of Pralmorelin as a diagnostic agent for evaluating GH-secretory capacity. The trade-off relative to Ipamorelin (the GH-selective member of the family) is broader receptor coverage, GHRP-2 engages the cortisol and prolactin axes at higher doses, which is a real confounder for any cellular or in vivo readout that touches those secondary axes. For compounding pharmacy buyers, Vialdyne releases GHRP-2 as a lyophilised powder against a ≥99.0% main-peak HPLC specification. SPPS access to the hexapeptide is straightforward, so the standard release packet centres on peak-integration RP-HPLC plus ESI-MS identity. Catalogue strengths are 5 mg and 10 mg, sized to typical bench-scale and research-dispensing workflows. The selection rule between GHRP-2 and Ipamorelin is mechanism-based: clean GH selectivity points to Ipamorelin; maximum GH-release amplitude with tolerable secondary-axis effects points to GHRP-2.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

158861-67-7

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 15 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 0.14 hours

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for GHRP-2; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

GHRP-2

VD260428-G210080 · 99.11%

VerifiedRequest full COA →

GHRP-2

VD260428-GR2081 · 99.64%

VerifiedRequest full COA →

GHRP-2

VD260428-G25079 · 99.50%

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. No authors listed. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004;5(4):236-239.
2. Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168-1172.
3. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998;83(7):2355-2360.
4. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614.
5. Zeng P, Li S, Zheng YH, Liu FY, Wang JL, Zhang DL, Wei J. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides. 2014;55:103-109.
6. Kinoshita Y, Tominaga A, Usui S, Arita K, Sakoguchi T, Sugiyama K, Kurisu K. The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison. Endocr J. 2013;60(1):97-105.

Frequently asked questions